ZNF649-AS1: ZNF649-AS1 is a long non-coding RNA (lncRNA) that has been implicated in various aspects of breast cancer. It has been found to regulate trastuzumab resistance in HER-2+ breast cancer cells through autophagy, along with another lncRNA called AGAAP2-AS1 [PMC9254371]. Down-regulation of ZNF649-AS1 can inhibit autophagy and reverse trastuzumab resistance in breast cancer with positive HER-2 [PMC9254371]. ZNF649-AS1 is associated with PTBP1 protein induced by H3K27ac modification, and this association promotes the transcriptional activity of the ATG5 gene, which is involved in autophagy [PMC9254371]. It has been reported that ZNF649-AS1 activates the transcription of ATG5 by recruiting PTBP1, indicating its stimulative effect on autophagy [PMC8811066]. The binding of ZNF649-AS1 to PTBP1 enhances the stability of ATG5 mRNA and promotes autophagy in breast cancer cells [PMC9868890]. In clinical treatment, upregulation of ZNF649-AS1 gene induced by H3K27ac modification may lead to autophagy and trastuzumab resistance through its binding to PTBP1 and promotion of ATG5 transcription [PMC10006230]. ZNF649-AS1 is also identified as one of the screened biomarkers for SPTB (spontaneous preterm birth) along with other genes such as FADS2, PCDHGB5, and MFSD4A [PMC7689379]. Knockdown of ZNF649-AS1 can reverse trastuzumab resistance by modulating ATG5 expression [PMC8473733]. Furthermore, in lung adenocarcinoma, ZNF649-AS1 is one of the independent predictors of tumor relapse, along with other lncRNAs such as LINC01819 and HNF4A-AS1 [PMC8773641].